Also, the comparative efficacy between anti‐TNFs is similar, but the meta‐analysis showed a trend toward lower adverse events profile for etrolizumab versus infliximab.
← all excerpts
Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials.
1
—
—